Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Ekso Bionics Holdings, Inc. is a global innovator in exoskeleton technology, specializing in the creation, production, sale, and leasing of these advanced devices across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. The company's operations are divided into two distinct segments: EksoHealth and EksoWorks. The EksoHealth division concentrates on engineering, manufacturing, and marketing exoskeletons designed for medical applications. Conversely, the EksoWorks segment develops and commercializes exoskeleton solutions intended for able-bodied individuals, empowering them to perform demanding, repetitive physical tasks for extended durations. Its product portfolio includes EksoNR, a sophisticated wearable bionic suit and rehabilitation tool. This device supports physical therapists and physicians in treating patients recovering from conditions such as acquired brain injury, stroke, and spinal cord injury. Additionally, the EksoUE is an assistive wearable device for the upper extremities, designed to lessen the gravitational load on the wearer's shoulders and arms. Ekso Bionics Holdings, Inc. also maintains a licensing agreement with Lockheed Martin Corporation. Founded in 2005, the company maintains its corporate headquarters in Richmond, California.
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers.
Target Price
The average target price of EKSO is 9.5 and suggests 19% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to decr